Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate
and therefore play key roles in the Krebs cycle and cellular homoeostasis. Major advances …

Dysregulating cellular metabolism is one of the emerging cancer hallmarks. Mitochondria
are essential organelles responsible for numerous physiologic processes, such as energy …

Patients with glioma whose tumors carry a mutation in isocitrate dehydrogenase 1
(IDH1R132H) are younger at diagnosis and live longer. IDH1 mutations co-occur with other …

Intratumoral genomic heterogeneity in glioblastoma (GBM) is a barrier to overcoming
therapy resistance. Treatments that are effective independent of genotype are urgently …

Mutations affecting isocitrate dehydrogenase (IDH) enzymes are prevalent in glioma,
leukemia, and other cancers. Although mutant IDH inhibitors are effective against leukemia …

The most frequently mutated metabolic genes in human cancer are those encoding the
enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2; these mutations have so far been …

Mutant isocitrate dehydrogenase 1 (IDH1-R132H; mIDH1) is a hallmark of adult gliomas.
Lower grade mIDH1 gliomas are classified into 2 molecular subgroups: 1p/19q …

Background Uncontrolled seizures in patients with gliomas have a significant impact on
quality of life and morbidity, yet the mechanisms through which these tumors cause seizures …

ONC201 is the first member of the imipridone family of anticancer drugs to enter the clinic for
the treatment of diverse solid and hematologic cancers. A subset of pediatric and adult …

Simple Summary Chondrosarcomas are cartilage tumours that often harbour a mutation in
one of the isocitrate dehydrogenase (IDH) genes. IDH mutations are important drivers at the …